合成生物学与绿色生物制造·2025-06-22 12:00Core Viewpoint - The article emphasizes the rapid development and potential of the synthetic biology sector, driven by technological breakthroughs, supportive policies, and increased investment, aiming for the establishment of over 20 pilot platforms for biomanufacturing by 2027 [1][2][12]. Group 1: Policy and Industry Collaboration - The Ministry of Industry and Information Technology and the National Development and Reform Commission have initiated a plan to cultivate biomanufacturing pilot platforms, targeting the establishment of over 20 by 2027 to facilitate industrial scaling [1][2]. - There is a notable synergy between policy and industry, with advancements in biomanufacturing technologies and significant investments from companies like Kasei Biotech and Jinbo Biotech, indicating a robust ecosystem for growth [2][12]. Group 2: Technological Advancements - Synthetic biology is reshaping production models, enabling more efficient and environmentally friendly biomanufacturing processes through breakthroughs in gene editing, enzyme engineering, and metabolic engineering [3][4]. - The CRISPR-Cas9 technology has revolutionized gene editing, making complex genetic operations simpler and more cost-effective, thus laying the groundwork for the synthetic biology industry's expansion [4][15]. Group 3: Company Innovations and Applications - Kasei Biotech focuses on developing bio-based materials, with products that significantly reduce carbon emissions by over 50% compared to traditional petroleum-based counterparts [5][9]. - Fubon Technology has established a comprehensive innovation system in the bio-agriculture sector, developing competitive products that enhance crop nutrient absorption and promote sustainable agricultural practices [5][8]. Group 4: Challenges and Solutions - The transition from laboratory innovations to industrial production is critical, with companies like Huaxi Biotech investing heavily in pilot transformation platforms to enhance China's biomanufacturing competitiveness [7][15]. - Companies face dual technical bottlenecks in synthetic biology, including challenges in microbial cell factory construction and downstream fermentation purification processes [15]. Group 5: Future Trends and Market Dynamics - The synthetic biology sector is expected to experience accelerated technological iterations and expanded application scenarios over the next 3-5 years, driven by AI integration and a focus on quality improvement [14][11]. - The industry is moving towards a more rational investment landscape, with a shift from chasing scale to recognizing the importance of technological capabilities and product validation [14][13].